Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer. Read the full release at https://lnkd.in/gUge-aBH
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Biotechnology
Indianapolis, Indiana 20,257 followers
Accelerating Precision Medicine™
About us
POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer
- Website
-
http://www.pointbiopharma.com
External link for POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Indianapolis, Indiana
- Type
- Public Company
- Founded
- 2019
- Specialties
- Radioligand, Radiopharmaceutical, Cancer, and Oncology
Locations
-
Primary
Get directions
4850 W 78th St
Indianapolis, Indiana 46268, US
Employees at POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Updates
-
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights. Read the full release at https://lnkd.in/gNBjuRe9
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
pointbiopharma.com
-
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies. Read the full release as it contains important information.
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
prnewswire.com
-
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company reposted this
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies. Read the full release as it contains important information.
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
prnewswire.com
-
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company reposted this
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies. Read the full release as it contains important information.
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
prnewswire.com
-
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies. Read the full release as it contains important information.
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
prnewswire.com
-
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands Enables the efficient expansion of surface targets for radioisotope delivery. Read the full release: https://lnkd.in/gZ2-2rVg
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Proteins Targeted Radioligands
pointbiopharma.com
-
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights. Read the full release at https://lnkd.in/gM_uUN2f
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights.
pointbiopharma.com
-
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177. Read the full release here https://lnkd.in/gCSdvD6D.
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177 | POINT Biopharma
pointbiopharma.com